Saturday 17 October 2026
Export XCUR’s income statement to Excel — free account
Exicure, Inc.
XCUR Healthcare Biotechnology
Exicure, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $500,000.00, down 98.3% from fiscal 2022. In the quarter to June 2026, EPS grew 56.1% and free cash flow grew 65.4%, each against the same quarter a year earlier.
1.11
0.01
−0.89%
Follow XCUR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(217.87%) | (92.47%) | (145.16%) | (168.37%) | |
| (71.27%) | (34.00%) | (58.53%) | (54.98%) | ||
ROIC |
(237.72%) | (1,469.79%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(288.68%) | (474.66%) | 1,379.97% | 496.05% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.22) | (1.24) | (1.27) | (1.05) | |
Free Cash Flow |
(7.71) | (7.80) | (8.10) | (6.70) | |
Capital Expenditures |
0.54 | 0.75 | — | — | |
| Other line items | |||||
Cash ROIC |
(67.72%) | (101.71%) | (172.25%) | (248.85%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | — | |
Interest Coverage |
(797.17) | — | — | — | |
Operating CF/Net income |
0.89 | 1.73 | 0.83 | 0.81 | |
Depreciation/Fixed assets |
0.98 | 1.50 | 2.09 | 2.08 | |
Capex/Depreciation |
1.05 | 1.63 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.31) | (1.36) | (1.27) | (1.05) | |
Capex per Share |
0.09 | 0.12 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates